Methacholine Test Compares Airway Response in Children With and Without Asthma
Compares airway sensitivity to methacholine testing in school children with asthma and healthy children.
Plain-language title generated from the registry record
Registry title: Methacholine Challenge Test in School Children With/Without Asthma RISKA
Key facts
- Where
- Helsinki, FinlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 7 and 15 years old?
Source: NCT07031102, who can take part
Where in Finland
- HUS Skin and Allergy HospitalHelsinki, FinlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Helsinki University Central Hospital
- Trial code
- NCT07031102
- Record updated
- 22 June 2025
- Original description
The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed. At the study visit, a methacholine challenge test measuring airway hyperresponsiveness and an exhaled nitric oxide measurement are performed. The effect of medication intensification in asthma patients is further assessed through a telephone interview 1-2 months after the medication adjustment.Read full original descriptionShow less
RISKA: Respiratory Irritability With School Kids With/Without Asthma - Assessment of Methacholine Responsiveness in Pediatric Asthma: A Comparative Study With Healthy Controls
The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed. At the study visit, a methacholine challenge test measuring airway hyperresponsiveness and an exhaled nitric oxide measurement are performed. The effect of medication intensification in asthma patients is further assessed through a telephone interview 1-2 months after the medication adjustment.
Inclusion: • Aged 7-15 years, both sexes; No diagnosis of asthma in childhood; No inhaled asthma medication during the previous 2 years; No wheezing or shortness of breath during the previous 2 years; Written informed consent from the participant and guardian; Aged 7-15 years, both sexes; Physician-diagnosed asthma (ICD-10 codes J45.0/J45.1/J45.9); Inhaled corticosteroid treatment for at least 6 months; Either:; Well-controlled asthma (c-ACT/ACT score ≥20) and no clinical need to intensify medication, or; Poorly controlled asthma with physician-confirmed need for intensified asthma medication.
Exclusion: • Premature birth before 32 gestational weeks; Other chronic cardiopulmonary or neurological conditions affecting airways (excluding asthma); Severe underlying illness such as malignancy; Beta-blocker medication; Active immunological disease.